PH12021553011A1 - SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE - Google Patents
SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASEInfo
- Publication number
- PH12021553011A1 PH12021553011A1 PH1/2021/553011A PH12021553011A PH12021553011A1 PH 12021553011 A1 PH12021553011 A1 PH 12021553011A1 PH 12021553011 A PH12021553011 A PH 12021553011A PH 12021553011 A1 PH12021553011 A1 PH 12021553011A1
- Authority
- PH
- Philippines
- Prior art keywords
- disorders
- compounds
- small molecule
- molecule inhibitors
- inducing kinase
- Prior art date
Links
- 102000003945 NF-kappa B Human genes 0.000 title 1
- 108010057466 NF-kappa B Proteins 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010037575 Pustular psoriasis Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 abstract 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855144P | 2019-05-31 | 2019-05-31 | |
| US201962907833P | 2019-09-30 | 2019-09-30 | |
| PCT/EP2020/065024 WO2020239999A1 (en) | 2019-05-31 | 2020-05-29 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021553011A1 true PH12021553011A1 (en) | 2022-11-07 |
Family
ID=71108552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/553011A PH12021553011A1 (en) | 2019-05-31 | 2020-05-29 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE |
Country Status (37)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989387T3 (es) * | 2019-05-31 | 2024-11-26 | Janssen Pharmaceutica Nv | Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| US20250282785A1 (en) * | 2022-05-11 | 2025-09-11 | Janssen Pharmaceutica Nv | Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase |
| CN119604499A (zh) * | 2022-05-11 | 2025-03-11 | 詹森药业有限公司 | 作为NFκB诱导激酶的抑制剂的吡咯烷酮衍生物 |
| US20240279230A1 (en) | 2022-12-22 | 2024-08-22 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
| WO2025020886A1 (zh) * | 2023-07-27 | 2025-01-30 | 浙江星浩澎博医药有限公司 | 氮杂喹唑啉环衍生物及其用途 |
| WO2025026901A1 (en) | 2023-07-28 | 2025-02-06 | Boehringer Ingelheim International Gmbh | Process for the manufacture of a her2 inhibitor |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| US7132428B2 (en) | 2003-07-03 | 2006-11-07 | Aventis Pharmaceuticals Inc. | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders |
| US7592363B2 (en) * | 2004-08-03 | 2009-09-22 | Wyeth | Indazoles |
| WO2006053277A2 (en) | 2004-11-12 | 2006-05-18 | Chippac, Inc. | Wire bond interconnection |
| CA2728767A1 (en) | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| US20110183975A1 (en) | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| EP2686314A1 (en) | 2011-03-16 | 2014-01-22 | F.Hoffmann-La Roche Ag | 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
| HK1206024A1 (en) | 2012-02-17 | 2015-12-31 | F. Hoffmann-La Roche Ag | Tricyclic compounds and methods of use therefor |
| US8859553B2 (en) | 2012-07-30 | 2014-10-14 | Astar Biotech Llc | Protein kinase inhibitors |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| MX2016002238A (es) | 2013-08-22 | 2016-05-31 | Hoffmann La Roche | Alcoholes de alquilino y metodos de uso. |
| RU2016110021A (ru) * | 2013-08-22 | 2017-09-27 | Ф. Хоффманн-Ля Рош Аг | Алкиниловые спирты и способы их применения |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| JP6603713B2 (ja) | 2014-10-23 | 2019-11-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体 |
| EP3209663B1 (en) | 2014-10-23 | 2018-12-12 | Janssen Pharmaceutica N.V. | New pyrazolopyrimidine derivatives as nik inhibitors |
| CA2960336C (en) | 2014-10-23 | 2023-03-07 | Janssen Pharmaceutica Nv | Compounds as nik inhibitors |
| US9981962B2 (en) | 2014-10-23 | 2018-05-29 | Janssen Pharmaceutica Nv | Pyrazole derivatives as NIK inhibitors |
| WO2016135163A1 (en) | 2015-02-25 | 2016-09-01 | F. Hoffmann-La Roche Ag | Alkynyl alcohols and methods of use |
| ES2776658T3 (es) | 2016-01-22 | 2020-07-31 | Janssen Pharmaceutica Nv | Nuevos derivados de cianoindolina con sustituyente heteroaromático de 6 miembros como inhibidores de NIK |
| WO2017125530A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
| EP3478675B1 (en) | 2016-06-30 | 2020-04-22 | Janssen Pharmaceutica NV | Heteroaromatic derivatives as nik inhibitors |
| JP6936814B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 |
| WO2018037058A1 (en) * | 2016-08-24 | 2018-03-01 | F. Hoffmann-La Roche Ag | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use |
| CN109641894B (zh) | 2016-08-24 | 2022-09-09 | 豪夫迈·罗氏有限公司 | 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法 |
| MX2019014665A (es) | 2017-07-06 | 2020-07-29 | Janssen Pharmaceutica Nv | Nuevos derivados de azaindolina sustituida como inhibidores de nik. |
| CN109810110B (zh) * | 2017-11-22 | 2023-01-24 | 中国科学院上海药物研究所 | 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途 |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| ES2989387T3 (es) * | 2019-05-31 | 2024-11-26 | Janssen Pharmaceutica Nv | Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb |
| SG11202113129UA (en) | 2019-05-31 | 2021-12-30 | Ikena Oncology Inc | Tead inhibitors and uses thereof |
| MX2021014115A (es) | 2019-05-31 | 2021-12-10 | Chiesi Farm Spa | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). |
| CA3139554A1 (en) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
-
2020
- 2020-05-29 ES ES20733688T patent/ES2989387T3/es active Active
- 2020-05-29 CN CN202410972792.2A patent/CN118908957A/zh active Pending
- 2020-05-29 DK DK20733688.4T patent/DK3976597T3/da active
- 2020-05-29 MY MYPI2021007053A patent/MY205653A/en unknown
- 2020-05-29 MX MX2021014679A patent/MX2021014679A/es unknown
- 2020-05-29 CR CR20210587A patent/CR20210587A/es unknown
- 2020-05-29 AU AU2020282005A patent/AU2020282005A1/en active Pending
- 2020-05-29 PH PH1/2021/553011A patent/PH12021553011A1/en unknown
- 2020-05-29 BR BR112021023796A patent/BR112021023796A2/pt unknown
- 2020-05-29 PE PE2021001987A patent/PE20220768A1/es unknown
- 2020-05-29 SM SM20240418T patent/SMT202400418T1/it unknown
- 2020-05-29 PT PT207336884T patent/PT3976597T/pt unknown
- 2020-05-29 CA CA3143350A patent/CA3143350A1/en active Pending
- 2020-05-29 SG SG11202112994WA patent/SG11202112994WA/en unknown
- 2020-05-29 HU HUE20733688A patent/HUE068694T2/hu unknown
- 2020-05-29 PL PL20733688.4T patent/PL3976597T3/pl unknown
- 2020-05-29 KR KR1020217042635A patent/KR20220027871A/ko active Pending
- 2020-05-29 SI SI202030499T patent/SI3976597T1/sl unknown
- 2020-05-29 TW TW109118004A patent/TWI850390B/zh active
- 2020-05-29 UY UY0001038721A patent/UY38721A/es unknown
- 2020-05-29 TW TW113125993A patent/TW202517638A/zh unknown
- 2020-05-29 JP JP2021570919A patent/JP7547387B2/ja active Active
- 2020-05-29 JO JOP/2021/0318A patent/JOP20210318A1/ar unknown
- 2020-05-29 RS RS20241148A patent/RS66105B1/sr unknown
- 2020-05-29 FI FIEP20733688.4T patent/FI3976597T3/fi active
- 2020-05-29 US US16/887,889 patent/US11254673B2/en active Active
- 2020-05-29 MA MA56038A patent/MA56038B1/fr unknown
- 2020-05-29 MD MDE20220374T patent/MD3976597T2/ro unknown
- 2020-05-29 HR HRP20241352TT patent/HRP20241352T1/hr unknown
- 2020-05-29 CN CN202080057418.XA patent/CN114222737B/zh active Active
- 2020-05-29 EP EP20733688.4A patent/EP3976597B1/en active Active
- 2020-05-29 LT LTEPPCT/EP2020/065024T patent/LT3976597T/lt unknown
- 2020-05-29 EP EP24188073.1A patent/EP4467199A3/en active Pending
- 2020-05-29 WO PCT/EP2020/065024 patent/WO2020239999A1/en active IP Right Grant
-
2021
- 2021-11-25 CL CL2021003142A patent/CL2021003142A1/es unknown
- 2021-11-25 IL IL288387A patent/IL288387B1/en unknown
- 2021-11-26 DO DO2021000244A patent/DOP2021000244A/es unknown
- 2021-11-30 SA SA521430960A patent/SA521430960B1/ar unknown
- 2021-12-13 US US17/549,057 patent/US11827634B2/en active Active
- 2021-12-27 CO CONC2021/0017838A patent/CO2021017838A2/es unknown
- 2021-12-28 EC ECSENADI202193623A patent/ECSP21093623A/es unknown
-
2023
- 2023-09-27 US US18/475,499 patent/US20240199605A1/en active Pending
-
2024
- 2024-08-28 JP JP2024146717A patent/JP2024167319A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430960B1 (ar) | NF-κB مثبطات جزيئية صغيرة لكيناز تحفيز | |
| EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| MX2022016415A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX371153B (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
| MX371150B (es) | NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). | |
| JOP20190262B1 (ar) | مثبطات بيرازول magl | |
| MX2017005284A (es) | Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk). | |
| GEP20227442B (en) | Boron containing pde4 inhibitors | |
| MX2019014665A (es) | Nuevos derivados de azaindolina sustituida como inhibidores de nik. | |
| BR112021022966A2 (pt) | Método para reduzir o tamanho do tumor | |
| MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| MX2021005273A (es) | Inhibidores de quinasa rock. | |
| MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. | |
| MX2023005681A (es) | Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol. | |
| EA201891687A9 (ru) | Новые замещённые производные цианиндолина в качестве nik-ингибиторов | |
| MX378444B (es) | Composiciones que inhiben a la enzima triosa fosfato isomerasa (tim) de trichomonas vaginalis para el tratamiento de la tricomoniasis. | |
| MY192305A (en) | Bipyrazole derivatives as jak inhibitors |